TATAINVEST Q1 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹152 Cr
verified against source
Revenue YoY
17.1%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Tata Elxsi reported a healthy Q1 FY24 with 17.1% YoY operating revenue growth despite macro headwinds, maintaining 29.6% EBITDA margin through strong operational discipline. Transportation delivered 17% YoY growth in constant currency with a strong deal pipeline including strategic SDV wins from leading Asian OEM and top-5 global OEM. Healthcare showed recovery with 3.2% QoQ growth, rebounding from two quarters of softness on the back of new product development deals. Media & communications remained muted at 0.2% QoQ growth but the company retained market share versus peers. PAT margin stood at 21.6%, impacted by higher effective tax rate due to SEZ tax holiday completion. Management guided for growth acceleration in Q2-Q4 with strong pipeline visibility in automotive, healthcare, and design, expecting to offset any continued softness in media. Deal conversion delays in transportation reflect customer caution but management remains confident of closures in Q2. Attrition dropped to 15.6% with 422 net employee additions. Risk: delayed deal conversions and macro uncertainty could impact H2 revenue trajectory if pipeline doesn't convert.
Colored figures show movement against the previous available record.
Guidance to track
- Management expressed confidence that strong deal pipeline in automotive, healthcare, and design businesses will drive accelerated revenue growth in subsequent quarters as deal closures materialize.
- Pipeline remains strong with large opportunities in SDV and EV spaces; management expects delayed deal closures from Q1 to materialize in Q2 and Q3 as macroeconomic conditions stabilize.
- Healthcare and life sciences demonstrated recovery with 3.2% QoQ growth and new product wins; management expects continued growth trajectory returning to earlier growth rates.
- Current utilization at 72-72.5% provides headroom; management aims to push utilization higher as business picks up and trained resources get deployed on projects.
Risks flagged
- Large deal closures are taking longer than expected due to customer caution on big bids in current macro environment. If Q2/Q3 closures don't materialize as expected, revenue growth could be impacted.
- Entire industry facing headwinds with peers showing degrowth; Tata Elxsi has held ground but absolute growth remains muted. Management declined to call bottom, waiting to assess Q2 deal closures before making projections.
- Wage hikes for senior staff will take effect from Q2 (July onwards), creating additional cost pressure. Analyst specifically questioned whether margin impact can be absorbed; management indicated it can be managed through operating leverage.
- Revenue from top 10 accounts now exceeds 51% and top 5 exceeds 42%, increasing customer concentration risk if any key accounts reduce engagement.
Key quotes
- The deal pipeline is still pretty strong. There are large opportunities that we are chasing, and we are really hopeful that we will have those closures in Q2 and the subsequent quarters.
- We have held our ground, even though we have not grown significantly, but I think we have done a very good creditable effort to maintain our business. Especially if you look at our top 5, top 10 customers, I think we've actually won deals and improved our market share as compared to our competition.
- The resource situation definitely has become a lot more easier. We are able to hire resources on need basis. But we are reducing the dependency on third-party contractors and filling positions using our own internal resources for better margins.
Research modules